WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 555924
CAS#: 201740-84-3 (C13-labeled)
Description: L-LEUCINE-13C6, also known as 13C6-D-Leucine or L-Leucine-1,2,3,4,5,5'-13C6, is a fully 13C labelled D-Leucine.
MedKoo Cat#: 555924
Name: L-Leucine-13C6
CAS#: 201740-84-3 (C13-labeled)
Chemical Formula: (*CH3)2*CH*CH2*CH(NH2)*COOH (*C is C13 labeled)
Exact Mass:
Molecular Weight: 137.1291
Elemental Analysis:
Synonym: 201740-84-3 (C13-labeled), 61-90-5 (unlabeled),
IUPAC/Chemical Name: L-Leucine-1,2,3,4,5,5'-13C6.
InChi Key: ROHFNLRQFUQHCH-YFKPBYRVSA-N
InChi Code: InChI=1S/C6H13NO2/c1-4(2)3-5(7)6(8)9/h4-5H,3,7H2,1-2H3,(H,8,9)/t5-/m0/s1
SMILES Code: N[C@@H](CC(C)C)C(O)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
| Biological target: | L-LEUCINE-13C6, also known as 13C6-D-Leucine or L-Leucine-1,2,3,4,5,5'-13C6, is a fully 13C labelled D-Leucine. |
| In vitro activity: | On the other hand, Leu (L-leucine) treatment sharply decreased the β-cell number, as measured by insulin immunostaining (Fig. 2B and C for quantification). Such data indicate that l-Leu treatment represses β-cell development. Reference: Diabetes. 2012 Feb;61(2):409-17. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3266409/ |
| In vivo activity: | This study has explored the hypothesis that reduced ribosome function contributes to RBS in zebrafish models and human cells. To study this cohesinopathy in a whole animal model this study used ESCO2-mutant and morphant zebrafish embryos, which have developmental defects mimicking RBS. Stimulation of the TOR pathway with L-leucine rescued many developmental defects of ESCO2-mutant embryos. Reference: PLoS Genet. 2013;9(10):e1003857. https://pubmed.ncbi.nlm.nih.gov/24098154/ |
The following data is based on the product molecular weight 137.1291 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | 1. Wu H, Dridi S, Huang Y, Baum JI. Leucine decreases intramyocellular lipid deposition in an mTORC1-independent manner in palmitate-treated C2C12 myotubes. Am J Physiol Endocrinol Metab. 2020 Feb 1;318(2):E152-E163. doi: 10.1152/ajpendo.00241.2019. Epub 2019 Nov 26. PMID: 31770014. 2. Rachdi L, Aïello V, Duvillié B, Scharfmann R. L-leucine alters pancreatic β-cell differentiation and function via the mTor signaling pathway. Diabetes. 2012 Feb;61(2):409-17. doi: 10.2337/db11-0765. Epub 2011 Dec 30. PMID: 22210321; PMCID: PMC3266409. 3. Wang X, Wang X, Xie F, Sun Z, Guo B, Li F, Wang S, Wang Y, Tian Y, Zhao Y, Qian L. Leucine mediates cognitive dysfunction in early life stress-induced mental disorders by activating autophagy. Front Cell Neurosci. 2023 Jan 4;16:1060712. doi: 10.3389/fncel.2022.1060712. PMID: 36687518; PMCID: PMC9846360. 4. Xu B, Lee KK, Zhang L, Gerton JL. Stimulation of mTORC1 with L-leucine rescues defects associated with Roberts syndrome. PLoS Genet. 2013;9(10):e1003857. doi: 10.1371/journal.pgen.1003857. Epub 2013 Oct 3. PMID: 24098154; PMCID: PMC3789817. |
| In vitro protocol: | 1. Wu H, Dridi S, Huang Y, Baum JI. Leucine decreases intramyocellular lipid deposition in an mTORC1-independent manner in palmitate-treated C2C12 myotubes. Am J Physiol Endocrinol Metab. 2020 Feb 1;318(2):E152-E163. doi: 10.1152/ajpendo.00241.2019. Epub 2019 Nov 26. PMID: 31770014. 2. Rachdi L, Aïello V, Duvillié B, Scharfmann R. L-leucine alters pancreatic β-cell differentiation and function via the mTor signaling pathway. Diabetes. 2012 Feb;61(2):409-17. doi: 10.2337/db11-0765. Epub 2011 Dec 30. PMID: 22210321; PMCID: PMC3266409. |
| In vivo protocol: | 1. Wang X, Wang X, Xie F, Sun Z, Guo B, Li F, Wang S, Wang Y, Tian Y, Zhao Y, Qian L. Leucine mediates cognitive dysfunction in early life stress-induced mental disorders by activating autophagy. Front Cell Neurosci. 2023 Jan 4;16:1060712. doi: 10.3389/fncel.2022.1060712. PMID: 36687518; PMCID: PMC9846360. 2. Xu B, Lee KK, Zhang L, Gerton JL. Stimulation of mTORC1 with L-leucine rescues defects associated with Roberts syndrome. PLoS Genet. 2013;9(10):e1003857. doi: 10.1371/journal.pgen.1003857. Epub 2013 Oct 3. PMID: 24098154; PMCID: PMC3789817. |
